Modeling ALS with iPSC-derived motor neurons, microglia and astrocytes
Authors: Helena Raine, Jessica Tilman, David Wallbank, Sian Humphreys, and Sapna Vyas
Introduction
Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig’s disease, is a neurodegenerative disease characterised by the progressive degeneration of motor neurons in the spinal cord and the motor cortex. This degeneration of neurons ultimately results in respiratory failure and death around 3 years after diagnosis¹. There is no current cure for ALS or effective treatments available.
ALS is linked to various mutations, with the C9orf72 expansion, TDP-43, and SOD1 most frequently implicated in familial ALS, although these only correspond to 5-10% of ALS cases. Sporadic ALS makes up the remaining 90 to 95% of all cases of the disease².
Slow progress in the field has in part been due to the heterogeneity within this disease, and due to the lack of appropriate in vitro models and platforms for drug discovery to gain insight into the pathophysiology of ALS. Research into ALS has been primarily focused on animal models, cell lines and patient material, and except for SOD1G37R mice3, animal models have failed to show translatability to clinical outputs. Patient samples and post-mortem material are not scalable or reproducible enough to provide a reliable platform for drug discovery, further complicated by the quick progression of the disease.
Human induced pluripotent stem cells (iPSCs) have emerged as a valuable tool for disease modeling and drug discovery in neurodegeneration, providing scalable, reproducible and human-relevant models. The ability to genetically manipulate cells to introduce and correct mutations as well as utilising patient derived cells further adds value to these models in the study of heterogeneous conditions such as ALS and can provide a method to study large cohorts of samples for patient stratification.
axoCells™ iPSC-derived motor neurons from donors affected by ALS backgrounds – C9orf72 expansion, TDP-43 A382T, SOD1 D109Y and a donor unaffected by the disease were used to develop a model to study the morphological and functional differences between the neurons.
Additionally, a more physiologically relevant tri-culture model of motor neurons, astrocytes, and microglia was developed to further interrogate the role of neuroinflammation and cell to cell signalling in neuronal dysfunction. Future work will focus on expanding this work to include sporadic ALS lines.
Methods and assays
axoLines™ iPSCs
Fibroblasts from unaffected and ALS donors were reprogrammed to iPSCs using Sendai Virus.
axoCells™ iPSC-derived cells
iPSCs were differentiated to motor neuron progenitors using small molecule induction methods prior to cryopreservation. axoCells™ iPSC-derived motor neurons were differentiated from donors affected by ALS backgrounds (C9Orf72 expansion (ax0074), TDP-43 A382T (ax0079), SOD1 D109Y (ax0735)) and an unaffected donor (ax0076). axoCells™ motor neuron progenitors were thawed and matured to motor neurons over 21 days and quality control performed by immunocytochemistry for expression of HB9, ChAT, Islet-1, SMI-32, and TUJ1, as well as functional firing on an Incucyte® Live-Cell Analysis System.
iPSC-derived microglia were also differentiated using a small molecule induction method and cryopreserved as immature microglia. axoCells™ microglia were thawed and matured over 7 days prior to assessing expression of IBA-1, TMEM119, and CX3CR1 by immunocytochemistry.
iPSC-derived astrocytes were differentiated using small molecule induction methods prior to cryopreserving. Once thawed, axoCells™ astrocytes were cultured for 2 days and assessed for expression of EAAT2, GFAP, Nestin, S100, ALDH1, AQP4 and TUJ1.
A tri-culture model including each cell type was also developed, which is now available as a complete kit (ax0194).
Immunocytochemistry
The cells were fixed using 4% paraformaldehyde at room temperature (RT) for 20 minutes and washed in phosphate buffered saline (PBS). Cells were then permeabilised using 0.1% Triton X and blocked in 5% Donkey Serum. Primary Antibody SMI-32 was used to stain the motor neurons overnight. Secondary antibodies conjugated to FITC were then added for a 2-hour incubation at RT, prior to imaging using a Leica microscope.
Incucyte® Neuronal Activity Assay
iPSC-derived motor neuron progenitor cells from unaffected and disease lines were thawed and seeded at 40,000 cells per well of a 96-well plate. The neurons were matured for 21 days. On Day 5 – 7, cells were transduced using the Incucyte® Neuroburst Orange Lentivirus Reagent (Neuroburst Orange; Sartorius, 4736) a live-cell neuronal labeling reagent driven by a synapsin promoter, resulting in the long-term expression of an orange fluorescent calcium indicator. Spontaneous activity monitored throughout maturation up to Day 21 using an Incucyte® Live-Cell Analysis System and integrated Incucyte® Neuronal Activity Analysis Software Module.
Quantification of TDP-43 aggregation
iPSC-derived motor neurons from unaffected and ALS (C9orf72 expansion) donors were thawed and cultured for 3 days prior to adding sodium (Na) arsenite as a stressor to induce TDP-43 mislocalisation/aggregation for 2 hours. Cells were then fixed as described above and stained for total TDP-43 and TUJ1. Cells were imaged and quantification of nuclear and cytoplasmic staining performed by Nikon.






